About Alacris Theranostics GmbH

Alacris Theranostics’ mission is to exploit next generation sequencing and other omics data through its predictive modelling system ModCell™, to facilitate drug development and personalised medicine in oncology and other complex diseases. This approach was originally developed at the Max Planck Institute for Molecular Genetics in Berlin and is exclusively licensed to Alacris Theranostics.
Alacris Theranostics provides extensive bioinformatics expertise and well-equipped facilities, including a Next Generation Sequencing lab for clinical application and a powerful IT infrastructure.
Working together with clinics and industry leaders worldwide in the fields of personalised medicine, biomarker application, IT and drug development, Alacris Theranostics has developed a unique approach to solve the problems of personalised drug treatment.